Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Cut to $52.00 by Analysts at HC Wainwright

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target cut by equities research analysts at HC Wainwright from $54.00 to $52.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 40.18% from the stock’s previous close.

Several other equities research analysts have also issued reports on AGIO. JPMorgan Chase & Co. lowered their price objective on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Bank of America boosted their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Truist Financial increased their price target on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. The Goldman Sachs Group raised their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $42.78.

Agios Pharmaceuticals Trading Down 7.4%

Shares of NASDAQ:AGIO traded down $2.96 during trading on Tuesday, reaching $37.09. The company’s stock had a trading volume of 1,340,015 shares, compared to its average volume of 1,028,165. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The firm’s 50 day simple moving average is $33.26 and its two-hundred day simple moving average is $30.43. The stock has a market capitalization of $2.21 billion, a PE ratio of -5.12 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. The company’s quarterly revenue was up 137.7% on a year-over-year basis. Research analysts anticipate that Agios Pharmaceuticals will post -6.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at $25,000. Assetmark Inc. grew its position in shares of Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the first quarter valued at $40,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $49,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $72,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.